^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Excerpt:
...- A confirmed EBRAFV600E or KBRAFV600K mutation....
Trial ID:
Source:
Title:
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Excerpt:
...- Biopsy proven metastatic melanoma with the B-raf V600E or V600K mutations....
Trial ID:
More C2 evidence
Source:
Title:
The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation
Excerpt:
...- Signed written informed consent - Recheck the results of histological studies and paraffin blocks - Histologically confirmed cancer that is either Stage IIIc (unresectable) or ---Stage IV (metastatic), and determined to be BRAF V600E or V600K mutation-positive by the local laboratory. ...
Less C2 evidence
Source:
Title:
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Excerpt:
Twenty patients had BRAFV600E (67%), 9 had BRAFV600K (30%), and 1 had BRAFV600R melanoma (3%). Nearly all (28 of 30; 93%) patients experienced tumor regression with treatment. The median PFS was 22.0 weeks [95% confidence interval (CI), 13.0–31.0) and the median OS was 80.7 weeks (95% CI, 46.0–115.4; Table 1).
DOI:
10.1158/1078-0432.CCR-13-3122
Trial ID:
Source:
Title:
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Excerpt:
In 17 melanoma cell lines, RG7204 was a potent inhibitor of proliferation in those expressing BRAFV600E but not BRAFWT (Fig. 1). RG7204 also potently inhibited proliferation of melanoma cell lines expressing other codon 600 BRAF mutations (V600D, V600K, and V600R).
DOI:
10.1158/0008-5472.CAN-10-0646
